EMA grants orphan designation to AMT for hemophilia B gene therapy
Links shared publicly online about this topic.
- 0total visits
EMA grants orphan designation to AMT for hemophilia B gene therapy
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that the European Medicines Agency (EMA) has granted orphan designation for its gene therapy program for the treatment of hemophilia B. Orphan designation in the European Union provides several benefits including 10 years of market exclusivity from product launch and access to the central authorization procedure.
View full resource at news-medical.net
Tags: Hemophilia, Parkinson's Disease, Disease and Condition, Genes, disease, Medical, Medicine
Most Recently Shared on November 16, 2011 at 5:30 pm By:
Parkinson's Disease: EMA grants orphan designation to AMT for hemophilia B gene therapy: Amsterdam Molecular The... http://t.co/li0WP3Nm
FDA grants orphan designation for AMT's hemophilia gene therapy program
news-medical.net — “Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that the U.S. Food and Drug Administration has granted orphan drug designation to its gene therapy program for the treatment of hemophilia B.” View full resource at news-medical.net
Most Recently Shared on January 4, 2012 at 3:35 pm By:
FDA grants orphan designation for AMT's hemophilia gene therapy program: Amsterdam Molecular Therapeutics, a lea... http://t.co/2rQWPl5w
Advertisement
